Atrial Fibrillation in Beta-Thalassemia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital of Ferrara
About this trial
The study aims to evaluate the clinical, laboratory and instrumental differences that exist between beta-thalassemia patients with atrial fibrillation and those not affected by arrhythmia.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Transfusion-dependent Beta-thalassemia;
Follow-Up at the Cardiology Unit of the University Hospital of Ferrara;
Electrocardiogram performed;
Echocardiogram performed.
Disqualifiers
Age <18 years;
State Of pregnancy;
Inability to give informed consent.
Trial population
Transfusion-dependent Beta-thalassemia patients
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
350 Participants
are grouped into 1 trial groupGroup A: Beta-thalassemia
Trial outcomes
Primary outcomes
1
Atrial fibrillation
New onset of Atrial Fibrillation documented at ECG
Time frame
10 yearsSecondary outcomes
1
Thromboembolism
Stroke or peripheral embolization
Time frame
10 years2
Epicardial adipose tissue
Thickness of fat depot in epicardial region
Time frame
Baseline3
SGLT2 effect on Hb
rise in hemoblogin levels
Time frame
6 months4
Atrial fibrillation recurrences
Recurrences of AF during follow-up
Time frame
10 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov